This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leighl, N. B. Articles by Goodwin, P. J. Search for Related Content PubMed PubMed Citation Articles by Leighl, N. B. Articles by Goodwin, P. J. Social Bookmarking                            What's this?

Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non–Small-Cell Lung Cancer

From the Department of Medical Oncology, Princess Margaret Hospital/University Health Network, and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Address reprint requests to Natasha Leighl, MD, Princess Margaret Hospital, 5-222, 610 University Ave, Toronto, Ontario, Canada M5G 2M9; email: Natasha.Leighl{at}uhn.on.ca

PURPOSE: To determine the cost-effectiveness (CE) of second-line docetaxel compared with best supportive care (BSC) in the TAX 317 trial, a randomized clinical trial of second-line chemotherapy in non–small-cell lung cancer.

METHODS: A retrospective CE analysis of the TAX 317 trial was undertaken, evaluating direct medical costs of therapy from the viewpoint of Canada’s public health care system. Costs were derived in 1999 Canadian dollars, and resource use was determined through prospective trial data.

RESULTS: The incremental survival benefit in the docetaxel arm over BSC was 2 months (P = .047). The CE of docetaxel was $57,749 per year of life gained. For patients treated with docetaxel 75 mg/m², the CE was $31,776 per year of life gained. In univariate sensitivity analyses, CE estimates were most sensitive to changes in survival, ranging from $18,374 to $117,434 with 20% variation in survival at the recommended dose. The largest cost center in both arms was hospitalization, followed by the cost of drugs, investigations, radiotherapy, and community care. BSC patients had fewer hospitalizations than patients in the chemotherapy arm and were more often palliated at home.

CONCLUSION: Although the decision to treat should not be based on economic considerations alone, our CE estimate of $31,776 per year of life gained (at the currently recommended dose of docetaxel) is within an acceptable range of health care expenditures, and the total costs of therapy are similar to those of second-line palliative chemotherapy for other solid tumors.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. I. Cherny, A. P. Abernethy, F. Strasser, R. Sapir, D. Currow, and S. Y. Zafar Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review J. Clin. Oncol., November 10, 2009; 27(32): 5476 - 5486. [Abstract] [Full Text] [PDF]

				R. Ng, B. Hasan, N. Mittmann, M. Florescu, F. A. Shepherd, K. Ding, C. A. Butts, Y. Cormier, G. Darling, G. D. Goss, et al. Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer--A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., June 1, 2007; 25(16): 2256 - 2261. [Abstract] [Full Text] [PDF]

				D. R. Gandara and A. M. Davies Oral Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer: The Bottom Line J. Clin. Oncol., June 20, 2006; 24(18): 2700 - 2701. [Full Text] [PDF]

				L Maslove, N Gower, S Spiro, R Rudd, R Stephens, and P West Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer Thorax, July 1, 2005; 60(7): 564 - 569. [Abstract] [Full Text] [PDF]

				D. G. Fryback and B. M. Craig Measuring Economic Outcomes of Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 134 - 141. [Abstract] [Full Text] [PDF]